Interferon gamma as a potential therapy for Friedreich ataxia
β Scribed by Tomassini, B.; Arcuri, G.; Fortuni, S.; Sandi, C.; Ezzatizadeh, V.; Casali, C.; Condo, I.; Malisan, F.; Al-Mahdawi, S.; Pook, M.; Testi, R.
- Book ID
- 123441489
- Publisher
- Elsevier Science
- Year
- 2013
- Tongue
- English
- Weight
- 63 KB
- Volume
- 333
- Category
- Article
- ISSN
- 0022-510X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
TALEs targeting a promoter sequence and fused with a transcription activation domain (TAD) may be used to specifically induce the expression of a gene as a potential treatment for haploinsufficiency. This potential therapeutic approach was applied to increase the expression of frataxin in fibroblast
Interferons (IFN) have had increasing clinical usage in the treatment of a variety of disorders, at times being used in combination with chemo-or radiotherapy. However, interferons may have inhibitory effects on hematopoietic stem cell proliferation and the effects of this cytokine's use on long-ter
## Abstract ## Background Friedreich ataxia is a slowly progressive neurodegenerative disease caused by reduced expression of frataxin as a result of a GAA repeat expansion in the first intron of the __FRDA__ gene. We report here the development of a sensitive cellular assay for frataxin expressio